Commonwealth Equity Services LLC Sells 10,326 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Commonwealth Equity Services LLC cut its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 15.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 55,673 shares of the biotechnology company’s stock after selling 10,326 shares during the period. Commonwealth Equity Services LLC’s holdings in Arrowhead Pharmaceuticals were worth $3,696,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ARWR. Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $29,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $32,000. WPG Advisers LLC boosted its holdings in Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 471 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,065 shares of company stock valued at $1,912,662 over the last ninety days. 3.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ARWR. Sanford C. Bernstein boosted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. Weiss Ratings lowered Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.80.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $73.86 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.30 and a 52-week high of $82.26. The business’s 50 day moving average price is $71.42 and its two-hundred day moving average price is $65.94. The firm has a market cap of $10.40 billion, a PE ratio of -34.35 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the firm earned $2.75 earnings per share. Arrowhead Pharmaceuticals’s revenue for the quarter was down 86.4% on a year-over-year basis. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.